Cancer Genetics (CGIX) Misses Q4 EPS by 2c

Cancer Genetics (NASDAQ: CGIX) reported Q4 EPS of ($0.48), $0.02 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $5.5 million versus the consensus estimate of $7 million.

For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c